LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

LLY

760.26

-0.44%↓

JNJ

175.17

-1.14%↓

ABBV

221.41

+0.22%↑

UNH

336.19

-1.48%↓

AZN

76.95

-0.91%↓

Search

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

25.28 -1.63

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.28

Max

25.63

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.8M

-57M

Verkoop

35K

730K

Winstmarge

-7,753.425

Werknemers

186

EBITDA

-1.1M

-63M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+114.15% upside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

180M

1.6B

Vorige openingsprijs

26.91

Vorige sluitingsprijs

25.28

Nieuwssentiment

By Acuity

21%

79%

40 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 sep 2025, 23:01 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sep 2025, 22:48 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sep 2025, 21:59 UTC

Winsten

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sep 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

17 sep 2025, 23:39 UTC

Marktinformatie

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sep 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sep 2025, 22:19 UTC

Acquisities, Fusies, Overnames

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sep 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sep 2025, 21:00 UTC

Winsten

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sep 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

17 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 sep 2025, 19:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 19:59 UTC

Marktinformatie

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sep 2025, 19:07 UTC

Marktinformatie

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sep 2025, 18:43 UTC

Marktinformatie

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sep 2025, 18:38 UTC

Marktinformatie

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sep 2025, 18:20 UTC

Marktinformatie

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sep 2025, 18:18 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 18:18 UTC

Marktinformatie

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sep 2025, 18:14 UTC

Marktinformatie

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sep 2025, 17:59 UTC

Marktinformatie

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sep 2025, 17:15 UTC

Acquisities, Fusies, Overnames

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sep 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sep 2025, 16:51 UTC

Winsten

Correct: Exor 1H Net Loss -EUR624M

17 sep 2025, 16:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 sep 2025, 16:34 UTC

Marktinformatie

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sep 2025, 16:25 UTC

Winsten

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sep 2025, 16:23 UTC

Winsten

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

114.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 52.38 USD  114.15%

Hoogste 67 USD

Laagste 38 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

40 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat